Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia
- 17 Downloads
We hypothesized that treatment-related weight loss is associated with worse outcomes following HSCT. Overall, 184 patients with AML who underwent induction therapy were classified according to d-BMI (BMI at transplant minus BMI at diagnosis) (kg/m2) as < −2, − 2 to + 2, and > + 2. At 1 year, OS was 67.9% (95% CI, 60.7–74.2), DFS was 64.1% (95% CI, 56.7–70.6), and GRFS was 40.2% (95% CI, 33.1–47.2). For d-BMI groups < − 2, − 2 to + 2, and > + 2, GRFS at 1 year was 16.1% (95% CI, 5.1–31.4), 45.4% (95% CI, 36.4–53.7), and 41.7% (95% CI, 22.2–60.1), respectively (P = 0.0067). Multivariate analysis showed that both worse OS (HR, 1.78; 95% CI, 1.02–3.14; P = 0.007) and GRFS (HR, 2.34; 95% CI, 1.26–4.35; P = 0.007) were associated with reduced BMI (d-BMI < − 2). Treatment-related weight reduction in AML was associated with poor outcome after HSCT.
KeywordsAML Treatment-related weight loss BMI HSCT
I appreciate for all authors who participated in the research and preparation of the manuscript. I would like to show my deepest gratitude to my supervisor, Dr. Etsuko-Yamazaki, Dr. Shin-Fujisawa, Dr. Heiwa-Kanamori, and Prof. Hideaki-Nakajima. This work was supported by Yokohama Cooperative Study Group for Hematology (YACHT).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest. A summary of relevant information will be published with the manuscript.
- 5.Le Blanc K, Ringden O, Remberger M. A low body mass index is correlated with poor survival after allogeneic stem cell transplantation. Haematologica. 2003;88:1044–52.Google Scholar
- 7.Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–33.Google Scholar
- 9.Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood. 2011;117:2358–65.CrossRefGoogle Scholar
- 10.Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 study. Blood. 2011;117:2366–72.CrossRefGoogle Scholar
- 11.WHO. Technical report series 854. Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. Geneva: World Health Organization; 1995.Google Scholar
- 12.Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2004;21:4642–9.CrossRefGoogle Scholar
- 15.Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–220.Google Scholar
- 19.Fuji S, Takano K, Mori T, Eto T, Taniguchi S, Ohashi K, et al. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. BMT. 2014;49:1505–12.Google Scholar